Ranking Profile - Lumos Pharma Inc
Introduction
Lumos Pharma Inc (Lumos Pharma), formerly NewLink Genetics Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new therapies for the treatment of unmet medical needs of rare diseases. The company’s lead investigating candidate, LUM-201 (ibutamoren) is an oral growth hormone stimulating therapy for the treatment of pediatric growth hormone deficiency (PGHD), turner syndrome, children born small for gestational age (SGA), and other rare endocrine disorders. Lumos Pharma is headquartered in Austin, Texas, the US.
Company info
| Country (HQ): | United States |
| Sector: | Pharmaceuticals and Healthcare |
| Market Cap (US$ m): | 27 |
| Revenue (US$ m): | 2 (2022) |
Innovation ranking
Innovation score
Closest peers in the Pharmaceuticals and Healthcare sector
Innovation Ranking
Johnson & Johnson
United States
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd
Switzerland
Pharmaceuticals and Healthcare
Lumos Pharma Inc
United States
Pharmaceuticals and Healthcare
EyeGate Pharmaceuticals Inc
United States
Pharmaceuticals and Healthcare
Shin Poong Pharm Co Ltd
South Korea
Pharmaceuticals and Healthcare
Are you ranked? Get the Innovation Ranking Report
-
Company Ranking Report
- If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
- Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
- Contextualised information on the company's standing in relation to peers
- Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
- Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
- Rosettes
- Certificate of Achievement
- Press release
